Suez, Egypt – Bukyline Pharmaceutical Co., Ltd. completed a significant facility upgrade in 2024, marking a milestone in its mission to advance animal health. With surging global demand for pet and livestock medications, the company introduced cutting-edge automation, dramatically enhancing production capacity and efficiency.

This upgrade optimized the supply chain, ensuring consistent access to high-quality raw materials, and paved the way for the launch of the standout Camel Respiratory Clear Tablet in late 2024. Praised for its natural ingredients and exceptional efficacy, this product has become a go-to solution for seasonal respiratory challenges. Production Manager Mark Thompson noted, “Through innovation and teamwork, we ensure every batch meets the highest standards.” The transformation resolved production bottlenecks and strengthened Bukyline’s position in a competitive industry. The company views this upgrade as a turning point, setting the stage for future global growth